http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016116942-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_70ec10dc769f2b57a961e2b165063897 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2015-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b35bea6c481556b12ce11225edf98d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f32a595266944a96d1ce220ffca26b1d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09cc5b0723d5b78a899a89438e286551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_091e743aff456e802a5af713a7f09b7c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37e7c49ad0ca5c0a099c552cd1ea9478 |
| publicationDate | 2016-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2016116942-A1 |
| titleOfInvention | Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin |
| abstract | The present invention relates to a novel synergistically active pharmaceutical compound, such as a supramolecular complex or an adduct or a co-crystal, comprising Ticagrelor with salts of aspirin (acetyl salicylic acid), preferably with sodium salt of aspirin ('The Compound 1'). The novel pharmaceutical compound, 'The Compound Γ, has distinct physico-chemical properties e.g. melting point, IR, powder XRD, DSC and TGA, which are different from the physico-chemical properties of its constituents. The novel pharmaceutical compound, 'The Compound 1 ' shows improved dissolution profile, in vitro and in vivo efficacy with respect to Ticagrelor. The present invention also describes processes for the preparation of novel pharmaceutical compounds, 'The Compound 1', its characterization, use in pharmaceutical composition and finally use in manufacture of medicament for use in prevention and/or treatment of arterial thrombotic complications in patients with coronary artery, cerebrovascular peripheral vascular disease and to methods of treating such disease in the human or animal body, by administering a therapeutically effective dose. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017324655-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10905691-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106619549-A |
| priorityDate | 2015-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 184.